Cytokinetics Inc. (CYTK) Trading Down 1.3%
Shares of Cytokinetics Inc. (NASDAQ:CYTK) traded down 1.3% on Monday . The stock traded as low as $10.32 and last traded at $10.36, with a volume of 410,200 shares trading hands. The stock had previously closed at $10.50.
A number of analysts recently commented on the stock. FBR & Co reissued a “buy” rating and set a $24.00 price objective on shares of Cytokinetics in a report on Tuesday, June 21st. Piper Jaffray Cos. reissued an “overweight” rating and set a $24.00 price objective on shares of Cytokinetics in a report on Tuesday, July 12th. Needham & Company LLC reissued a “buy” rating and set a $17.00 price objective on shares of Cytokinetics in a report on Thursday. JMP Securities reissued a “buy” rating and set a $17.00 price objective on shares of Cytokinetics in a report on Tuesday, August 2nd. Finally, Zacks Investment Research downgraded shares of Cytokinetics from a “buy” rating to a “hold” rating in a report on Friday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $18.13.
The firm’s market cap is $411.32 million. The stock’s 50 day moving average is $11.31 and its 200 day moving average is $8.73.
Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.02. On average, analysts expect that Cytokinetics Inc. will post ($1.30) EPS for the current fiscal year.
Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.